ArticleFrontiers in oncology2025
Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: a study based on ultrasound and clinicopathological features.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Nomogram Integrating Clinical and Ultrasonographic Features for Preoperative Differentiation of Invasive Ductal Carcinoma and Invasive Lobular Carcinoma of the Breast.Diagnostics (Basel, Switzerland) · 2026Article
- Early prediction of neoadjuvant chemotherapy efficacy among patients with triple-negative breast cancer using an ultrasound-based radiomics nomogram.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Article
- Impact of Hashimoto's thyroiditis on ultrasound diagnosis of papillary thyroid carcinoma: a retrospective study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the application value of ultrasound in evaluating the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer and construct a nomogram prediction model for pathological complete response (pCR) following different cycles of NAC based on ultrasound and clinicopathological features, and further investigate the optimal prediction cycle. Methods: A total of 249 breast cancer patients who received NAC were recruited. Ultrasound assessment was performed before NAC and after two cycles of NAC (NAC2), four cycles of NAC (NAC4), and six cycles of NAC (NAC6). All patients underwent surgical resection after NAC6 and the samples were sent for histopathological and immunohistochemical examination. Clinical efficacy was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST). Pathological efficacy was determined according to the Miller-Payne evaluation system (MP); grade 5 was classified as pCR group, while Grades 1-4 were classified as the non-pCR group (npCR). The patients were randomly divided into the training set and the validation set at a ratio of 7:3. The ultrasound and clinicopathological features of the training set were compared, and a nomogram prediction model was constructed based on these features. Finally, the ROC curve, calibration curve, and DCA were used for verification. Result: Among the 249 patients, 71 (28.5%) achieved pCR, whereas the remaining 178 (71.5%) exhibited npCR. The maximum tumor diameter measured by ultrasound after NAC6 was 1.20 (0.70, 2.10) cm, which was significantly positively correlated with the maximum tumor diameter measured by pathology after surgical resection ( Conclusion: Regardless of the cycle of NAC, patients with a small tumor, no posterior shadow, a valid RECIST, and a negative PR were more likely to achieve pCR. Evaluation after NAC2 can provide early predictive value in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.